| Palonosetron | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
| Palonosetron | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
| Palonosetron | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
| Palonosetron | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
| Palonosetron | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.29E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | |
| Palonosetron | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Palonosetron | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | |
| Palonosetron | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Palonosetron | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
| Palonosetron | hsa01100 | Metabolic pathways | 4.11E-02 | 7 | P30041, P20839, P08237, Q86XP1, Q9UHK6, Q86VZ5, Q9NVH6 | PRDX6, IMPDH1, PFKM, DGKH, AMACR, SGMS1, TMLHE | More | |
| Palonosetron | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | |
| Palonosetron | hsa03040 | Spliceosome | 6.28E-03 | 6 | Q14562, O43143, O60508, Q07955, Q01130, Q13243 | DHX8, DHX15, CDC40, SFRS1, SFRS2, SFRS5 | More | |
| Palonosetron | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | |
| Palonosetron | hsa04024 | cAMP signaling pathway | 4.38E-02 | 4 | P42338, P0DP23, Q13370, Q13009 | PIK3CB, CALM1, PDE3B, TIAM1 | More | |
| Palonosetron | hsa04070 | Phosphatidylinositol signaling system | 4.86E-02 | 3 | P0DP23, P42338, P27987 | CALM1, PIK3CB, ITPKB | More | |
| Palonosetron | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | |
| Palonosetron | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Palonosetron | hsa04144 | Endocytosis | 4.10E-02 | 3 | O75351, P62491, Q14161 | VPS4B, RAB11A, GIT2 | More | |
| Palonosetron | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | |
| Palonosetron | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
| Palonosetron | hsa04330 | Notch signaling pathway | 7.49E-03 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | |
| Palonosetron | hsa04360 | Axon guidance | 1.71E-02 | 4 | P20827, O95631, P42338, P23528 | EFNA1, NTN1, PIK3CB, CFL1 | More | |
| Palonosetron | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | |
| Palonosetron | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
| Palonosetron | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | |
| Palonosetron | hsa04613 | Neutrophil extracellular trap formation | 1.73E-02 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Palonosetron | hsa04650 | Natural killer cell mediated cytotoxicity | 2.94E-02 | 3 | P16298, P50591, Q02750 | PPP3CB, TNFSF10, MAP2K1 | More | |
| Palonosetron | hsa04659 | Th17 cell differentiation | 4.38E-02 | 4 | P42224, P14784, P40189, P08238 | STAT1, IL2RB, IL6ST, HSP90AB1 | More | |
| Palonosetron | hsa04666 | Fc gamma R-mediated phagocytosis | 3.08E-02 | 3 | P42338, P23528, P14598 | PIK3CB, CFL1, NCF1 | More | |
| Palonosetron | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
| Palonosetron | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Palonosetron | hsa04914 | Progesterone-mediated oocyte maturation | 2.97E-03 | 6 | Q17RY0, P42338, Q13370, P08238, P51812, Q02750 | CPEB4, PIK3CB, PDE3B, HSP90AB1, RPS6KA3, MAP2K1 | More | |
| Palonosetron | hsa04919 | Thyroid hormone signaling pathway | 3.71E-02 | 2 | P26678, P08237 | PLN, PFKM | More | |
| Palonosetron | hsa04924 | Renin secretion | 3.77E-02 | 2 | Q13370, P0DP23 | PDE3B, CALM1 | More | |
| Palonosetron | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | |
| Palonosetron | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Palonosetron | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | |
| Palonosetron | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Palonosetron | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Palonosetron | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Palonosetron | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | |
| Palonosetron | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | |
| Palonosetron | hsa05144 | Malaria | 3.09E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
| Palonosetron | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Palonosetron | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | |
| Palonosetron | hsa05168 | Herpes simplex virus 1 infection | 1.15E-02 | 8 | P42224, Q07955, Q01130, Q13243, P42338, Q13398, Q03923, Q9UDV6 | STAT1, SFRS1, SFRS2, SFRS5, PIK3CB, ZNF211, ZNF85, ZNF212 | More | |
| Palonosetron | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | |
| Palonosetron | hsa05200 | Pathways in cancer | 3.92E-02 | 9 | P42338, P08238, P42224, P43246, P14923, O75293, P0DP23, P14784, P40189 | PIK3CB, HSP90AB1, STAT1, MSH2, JUP, GADD45B, CALM1, IL2RB, IL6ST | More | |
| Palonosetron | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | |
| Palonosetron | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Palonosetron | hsa05212 | Pancreatic cancer | 1.72E-02 | 3 | P42338, P42224, O75293 | PIK3CB, STAT1, GADD45B | More | |
| Palonosetron | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | |
| Palonosetron | hsa05214 | Glioma | 1.72E-02 | 3 | P0DP23, P42338, O75293 | CALM1, PIK3CB, GADD45B | More | |
| Palonosetron | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | |
| Palonosetron | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Palonosetron | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Palonosetron | hsa05332 | Graft-versus-host disease | 3.70E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Palonosetron | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |
| Palonosetron | hsa05418 | Fluid shear stress and atherosclerosis | 3.73E-02 | 4 | P42338, P14598, P0DP23, P08238 | PIK3CB, NCF1, CALM1, HSP90AB1 | More | |
